**For Customers Shipping to Japan**
If your shipment is found to be an injectable product at customs, as of 2020, you will be required to present a Pharmaceutical Inspection Certificate.
If you are unable to provide one, please arrange for the shipment to be returned to the sender.
We will notify you once the product arrives at our company. We will then reship the product after receiving your payment.
5-Amino-1MQ 60 (60mg/10ml) ELIXIR SCIENCE
5-Amino-1MQ (5-amino-1-methylquinolinium) has attracted significant attention in metabolic research and clinical applications.
This guide provides detailed information on appropriate dosing protocols, dosage methods, and calculations to optimize treatment outcomes while minimizing potential risks.
Understanding 5-Amino-1MQ Peptide Therapy: 5-Amino-1MQ is highly active in adipose tissue and functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme associated with obesity and type 2 diabetes. NNMT inhibition increases NAD+ availability and affects metabolic processes, allowing the body to burn more calories and suppress glycogen and fat storage. This small, membrane-permeable molecule, with the chemical formula C10H11N2+, works by improving the removal of glucose from the blood, allowing cells to more quickly utilize available energy.
This compound exists in several forms:
Free base: Molecular weight 159.21 g/mol
Iodide salt: Molecular weight 286.11 g/mol (C10H11N2·I)
In studies, 5-amino-1MQ has shown promising results in the following areas:
Weight management through the promotion of fat metabolism [1]
Improvement of insulin sensitivity and glucose tolerance [2]
Potential applications in metabolic disorders [2]
Anti-aging and cellular energy [3]
Restoration of NAD+ levels [3]
Injection dosage: For injections (typically used in supervised clinical settings):
6 mg (1 ml) in the morning and 6 mg (1 ml) twice daily
One vial contains a 5-day supply.
Injection: Administer the injection 30 minutes after oral NMN intake.
Safety and Precautions: Based on available research, 5-amino-1MQ appears to have a favorable safety profile.
No significant adverse effects have been found in rodent studies. There is currently no established human toxicity profile. The most commonly reported side effect is potential sleep disturbance. An acclimation period may be required, and some subjects report decreased cardiovascular exercise tolerance during initial treatment.
Special Populations and Contraindications: Due to limited safety data, the following individuals should exercise caution or avoid use until further research is available: Pregnant or nursing women; People with chronic health conditions; People taking medications that may interact with 5-amino-1MQ. 5-amino-1MQ is a promising approach to addressing metabolic disorders through NNMT inhibition.
Preliminary safety data appear promising, but more comprehensive human studies are needed to establish definitive dosing guidelines and safety parameters. When considering 5-amino-1MQ as a therapeutic intervention, consultation with a qualified healthcare provider familiar with the mechanism and uses of this compound should be conducted to determine individualized dosage based on body weight, type of formulation, and specific health goals.
References
Dimet-Wiley, A., Wu, Q., Wiley, J., Eswar, A., Neelakantan, H., Savidge, T., & Watowich, S. (2022). The combination of a low-calorie diet and NNMT inhibition shapes a distinct microbiome in DIO mice. Scientific Reports, 12. https://doi.org/10.1038/s41598-021-03670-5
Liu, JR, Deng, ZH, Zhu, XJ, Zeng, YR, Guan, XX, & Li, JH (2021). The role of nicotinamide N-methyltransferase in obesity and type 2 diabetes. BioMed research international, 2021, 9924314. https://doi.org/10.1155/2021/9924314
Li, J., Sun, W., Zhu, X., Mei, Y., Li, W., & Li, J. (2024). Nicotinamide N-methyltransferase (NNMT): New hope for the treatment of aging and age-related diseases. Metabolites, 14.
https://doi.org/10.3390/metabo14060343
